# US 6,719,520 B2 · Method and compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,719,520 B2
- Document ID: US6719520B2
- Status: Granted
- Kind: B2
- Application number: 10/446,553
- Filed: 2003-05-28
- Published: 2004-01-15
- Granted: 2004-04-13
- Earliest claimed: 1998-10-08
- Assignees: SmithKline Beecham Corporation
- Inventors: Matthew Paul Coghlan; Ashley Edward Fenwick; David Haigh; Julie Caroline Holder; Robert John Ife; Alastair David Reith; David Glynn Smith; Robert William Ward
- Web page: https://patentgrep.com/patent/US6719520B2

## CPC

- C07D 207/456: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R1 and R3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof, and compounds of formula I.

## Claims

### Claim 1

3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2

A pharmaceutical composition comprising 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.